XellSmart Advances Phase 2 Parkinson’s Cell Therapy Trial
Suzhou, China | April 14, 2026 XellSmart has announced the initiation of a multicenter Phase II clinical trial evaluating...
neuroscience
Advertisement
GlycoNex Secures PMDA Nod for GNX1021 Phase 1 Trial
NEW TAIPEI CITY, TAIWAN, April 14, 2026 GlycoNex, Inc. has received approval from Japan’s Pharmaceuticals and Medical Devices Agency...
Revolution Medicines Reports Phase 3 Survival Gain PDAC
REDWOOD CITY, CALIFORNIA, USA, April 13, 2026 Revolution Medicines has announced positive topline results from its pivotal Phase 3...
Neurocrine Shows INGREZZA Persistence Edge in TD Study
SAN DIEGO, USA, April 14, 2026 Neurocrine Biosciences has presented new real-world evidence (RWE) demonstrating that patients treated with...
Praxis Precision Medicines Reports Strong Elsunersen Trial
Boston, Massachusetts, USA, April 6, 2026 Breakthrough Results in Rare Pediatric Epilepsy In a major advancement for precision neuroscience...
Advertisements
Tenvie Therapeutics Doses First Patient in TNV262 Trial
Brisbane, California, USA, April 6, 2026 First-in-Human Study Targets Inflammation Pathways In a significant milestone for clinical-stage biotech innovation,...
Neurocrine Acquires Soleno to Boost Rare Disease Portfolio
San Diego & Redwood City, California, USA, April 6, 2026 Strategic Acquisition Strengthens Rare Disease Leadership In a major...
Lilly to Acquire Centessa in $7.8B Pharma Deal
INDIANAPOLIS, USA & BOSTON, USA & LONDON, UK, March 31, 2026 Eli Lilly and Company has announced a definitive...
AI Drug Discovery Deal Expands CNS Pipeline Value
Hong Kong | March 30, 2026 AI Collaboration Accelerates CNS Drug Discovery Insilico Medicine and Tenacia Biotechnology have announced...
New Brain Health Institute Targets Lifelong Cognitive Resilience
CHICAGO, Feb. 2, 2026 — Northwestern University’s Feinberg School of Medicine has launched the Simpson Querrey Brain Health Institute,...
Advertisement
